BACKGROUND: The majority of studies that provide insights into the influence of the microbiome on the health of hematologic malignancy patients have concentrated on the transplant setting. Here, we sought to assess the predictive capacity of the gastrointestinal microbiome and its relationship to infectious outcomes in patients with acute myeloid leukemia (AML). METHODS: 16s rRNA-based analysis was performed on oral swabs and stool samples obtained biweekly from baseline until neutrophil recovery following induction chemotherapy (IC) in 97 AML patients. Microbiome characteristics were correlated with clinical outcomes both during and after IC completion. RESULTS: At the start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% confidence interval [CI], .18-.74) and higher relative abundance of Porphyromonadaceae (HR, 0.36; 95% CI, .18-.73) were associated with increased probability of remaining infection-free during neutropenia. A baseline stool Shannon diversity cutoff of <2 had optimal operating characteristics for predicting infectious complications during neutropenia. Although 56 patients received therapy >72 hours with a carbapenem, none of the patients had an infection with an extended spectrum β-lactamase-producing organism. Patients who received carbapenems for >72 hours had significantly lower α-diversity at neutrophil recovery (P = .001) and were approximately 4 times more likely to have infection in the 90 days following neutrophil recovery (HR, 4.55; 95% CI, 1.73-11.93). CONCLUSIONS: Our results suggest that gut microbiome evaluation could assist with infectious risk stratification and that improved targeting of antibiotic administration during IC could decrease subsequent infectious complications in AML patients.Baseline microbiome diversity is a strong independent predictor of infection during acute myeloid leukemia induction chemotherapy (IC) among clinical and microbiome covariates. Higher baseline levels of Porphyromonadaceae appear protective against infection, while carbapenem use is associated with consequences to the microbiome and infection susceptibility post-IC.
BACKGROUND: The majority of studies that provide insights into the influence of the microbiome on the health of hematologic malignancypatients have concentrated on the transplant setting. Here, we sought to assess the predictive capacity of the gastrointestinal microbiome and its relationship to infectious outcomes in patients with acute myeloid leukemia (AML). METHODS: 16s rRNA-based analysis was performed on oral swabs and stool samples obtained biweekly from baseline until neutrophil recovery following induction chemotherapy (IC) in 97 AMLpatients. Microbiome characteristics were correlated with clinical outcomes both during and after IC completion. RESULTS: At the start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% confidence interval [CI], .18-.74) and higher relative abundance of Porphyromonadaceae (HR, 0.36; 95% CI, .18-.73) were associated with increased probability of remaining infection-free during neutropenia. A baseline stool Shannon diversity cutoff of <2 had optimal operating characteristics for predicting infectious complications during neutropenia. Although 56 patients received therapy >72 hours with a carbapenem, none of the patients had an infection with an extended spectrum β-lactamase-producing organism. Patients who received carbapenems for >72 hours had significantly lower α-diversity at neutrophil recovery (P = .001) and were approximately 4 times more likely to have infection in the 90 days following neutrophil recovery (HR, 4.55; 95% CI, 1.73-11.93). CONCLUSIONS: Our results suggest that gut microbiome evaluation could assist with infectious risk stratification and that improved targeting of antibiotic administration during IC could decrease subsequent infectious complications in AMLpatients.Baseline microbiome diversity is a strong independent predictor of infection during acute myeloid leukemia induction chemotherapy (IC) among clinical and microbiome covariates. Higher baseline levels of Porphyromonadaceae appear protective against infection, while carbapenem use is associated with consequences to the microbiome and infection susceptibility post-IC.
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Ying Taur; Joao B Xavier; Lauren Lipuma; Carles Ubeda; Jenna Goldberg; Asia Gobourne; Yeon Joo Lee; Krista A Dubin; Nicholas D Socci; Agnes Viale; Miguel-Angel Perales; Robert R Jenq; Marcel R M van den Brink; Eric G Pamer Journal: Clin Infect Dis Date: 2012-06-20 Impact factor: 9.079
Authors: Gary H Lyman; Shannon L Michels; Matthew W Reynolds; Rich Barron; Karen Smoyer Tomic; Jingbo Yu Journal: Cancer Date: 2010-08-16 Impact factor: 6.860
Authors: Jessica R Galloway-Peña; Daniel P Smith; Pranoti Sahasrabhojane; Nadim J Ajami; W Duncan Wadsworth; Naval G Daver; Roy F Chemaly; Lisa Marsh; Shashank S Ghantoji; Naveen Pemmaraju; Guillermo Garcia-Manero; Katayoun Rezvani; Amin M Alousi; Jennifer A Wargo; Elizabeth J Shpall; Phillip A Futreal; Michele Guindani; Joseph F Petrosino; Dimitrios P Kontoyiannis; Samuel A Shelburne Journal: Cancer Date: 2016-05-03 Impact factor: 6.860
Authors: Jacob T Nearing; Jessica Connors; Scott Whitehouse; Johan Van Limbergen; Tamara Macdonald; Ketan Kulkarni; Morgan G I Langille Journal: Front Cell Infect Microbiol Date: 2019-02-19 Impact factor: 5.293
Authors: Christian Quast; Elmar Pruesse; Pelin Yilmaz; Jan Gerken; Timmy Schweer; Pablo Yarza; Jörg Peplies; Frank Oliver Glöckner Journal: Nucleic Acids Res Date: 2012-11-28 Impact factor: 16.971
Authors: Andrew Oliver; Kenza El Alaoui; Carolyn Haunschild; Julio Avelar-Barragan; Laura F Mendez Luque; Katrine Whiteson; Angela G Fleischman Journal: Microbiol Spectr Date: 2022-04-27
Authors: Samuel L Aitken; Pranoti V Sahasrabhojane; Dimitrios P Kontoyiannis; Tor C Savidge; Cesar A Arias; Nadim J Ajami; Samuel A Shelburne; Jessica R Galloway-Peña Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079
Authors: Tessa M Andermann; Farnaz Fouladi; Fiona B Tamburini; Bita Sahaf; Ekaterina Tkachenko; Courtney Greene; Matthew T Buckley; Erin F Brooks; Haley Hedlin; Sally Arai; Crystal L Mackall; David Miklos; Robert S Negrin; Anthony A Fodor; Andrew R Rezvani; Ami S Bhatt Journal: Transplant Cell Ther Date: 2021-07-16